SymBio Pharmaceuticals’ Losses Deepen as Equity Thins Despite 2026 Sales Rebound Forecast

An announcement from Symbio Pharmaceuticals Limited ( (JP:4582) ) is now available.

SymBio Pharmaceuticals reported a steep decline in consolidated net sales for fiscal 2025 to ¥1.31 billion, down 46.7% year-on-year, alongside widening operating and net losses, with profit attributable to owners of parent falling to a loss of ¥4.78 billion. The company’s financial position deteriorated markedly, with total assets shrinking, equity ratio plunging from 78.1% to 23.9%, and net assets per share dropping sharply, underscoring growing balance sheet pressure despite positive cash flow from financing activities and the continued suspension of dividends. For fiscal 2026, SymBio forecasts a near-tripling of net sales to ¥3.89 billion but still expects substantial operating and bottom-line losses, signaling that while revenue is projected to recover, profitability remains distant and capital structure risk will continue to be a key concern for investors and creditors.

The most recent analyst rating on (JP:4582) stock is a Sell with a Yen85.00 price target. To see the full list of analyst forecasts on Symbio Pharmaceuticals Limited stock, see the JP:4582 Stock Forecast page.

More about Symbio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange, focused on the development and commercialization of specialty drugs. The company’s portfolio centers on niche indications in oncology and other areas with high unmet medical needs, positioning it as a smaller player in the Japanese pharma market with a concentrated product and R&D base.

Average Trading Volume: 840,898

Technical Sentiment Signal: Sell

Current Market Cap: Yen5.06B

See more insights into 4582 stock on TipRanks’ Stock Analysis page.